I'll just leave these numbers here:
AKE current enterprise value = 4.8 billion AUD
AKE annualised net profit (from this quarter, neglecting all future growth and sale price increases) = 1.3 billion AUD
AKE growth plan NPV (discounted) = 30 billion AUD (seemingly fully funded to production?)
Livent's annualised net profit (using this quarter) = 500 million AUD. With a much more modest growth profile planned (and no idea of the planned project financials as either they are not reported or I can't find them).
I just can't believe this merger is fair at the proposed ratio. The market on both sides I think agrees. It seems impossible for AKE to rise under the uncertainty of the merger succeeding at the prescribed ratio, when you just buy Livent at discount prices. Livent won't rise under the uncertainty the merger fails. Until the merger outcome this is going to be painful I thinkalthough at what value can AKE just not be overlooked regardless, I don't know!!
- Forums
- ASX - By Stock
- AKE
- Ann: September quarterly activities report
Ann: September quarterly activities report, page-65
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AKE (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, CEO
James Graham
CEO
Previous Video
Next Video
SPONSORED BY The Market Online